Oasis has released a stripped-back acoustic version of their iconic track "Morning Glory," offering fans a fresh take on the classic ahead of the 30th anniversary deluxe edition of their seminal 1995 album. The unplugged rendition, produced and mixed by Noel Gallagher and engineer Callum Marinho using the original master recordings, showcases Liam Gallagher's vocals against a backdrop of acoustic guitar and tambourine, with a mid-song piano break adding a jazzy interlude to the arrangement.

The track is part of a special collection featuring acoustic versions of five fan favorites from the album, including "Cast No Shadow," "Wonderwall," "Champagne Supernova," and the previously released "Acquiesce." These unplugged recordings will appear as bonus tracks on the (What's The Story) Morning Glory? (30th Anniversary Deluxe Edition), set for release on October 3 via Big Brother Recordings. The deluxe edition is currently available for pre-order, with the new "Morning Glory (Unplugged)" accompanied by a visualiser highlighting the refreshed sonic landscape.

Originally released in 1995, (What's The Story) Morning Glory? cemented Oasis as global icons, delivering timeless anthems that have sold over 22 million copies worldwide. The album remains the UK's third best-selling studio album of all time and was recently named the Official Most Streamed Album of the '90s. The 30th anniversary reissue includes the original tracklisting alongside the five unplugged bonus tracks, providing both nostalgia and new material for dedicated fans.

The release comes as Oasis continues their sold-out reunion tour, with upcoming shows at London's Wembley Stadium this weekend before moving to South Korea, Japan, Australia, and South America. The tour has already included a successful North American run and multiple nights at Wembley, demonstrating the enduring appeal of the Britpop legends as they celebrate three decades of musical influence.

Global medical technology company Convatec has announced plans to establish a new flagship research and development hub in Manchester as part of a £500 million investment in the United Kingdom. The FTSE100-listed firm, which specializes in products for chronic wounds, diabetes, urinary incontinence, and stomas, will relocate its R&D operations from Deeside to Bruntwood SciTech's CityLabs 4.0 facility, scheduled to open in 2027. This strategic move represents a significant commitment to the UK's life sciences sector at a time when several other pharmaceutical companies have been shifting investments overseas.

The new Manchester facility will become one of the largest centers in Convatec's global network, spanning 125,000 square feet across seven storeys in the £42 million CityLabs 4.0 building. Located on Hathersage Road facing the Manchester Royal Infirmary, St Mary's and Royal Manchester Children's Hospital, the state-of-the-art facility will focus on research in four key therapeutic areas: advanced wound care, ostomy care, continence care, and infusion care. The company cited Manchester's "vibrant life sciences ecosystem, which includes leading universities, hospitals, and research institutions" as the primary reason for selecting the location.

Approximately 200 staff will be employed at the new Manchester hub, with most positions transferring from Convatec's existing R&D operation in Deeside, North Wales, which has served as a major research center since 1996. The company emphasized that no redundancies are planned as a consequence of the relocation and that the Deeside manufacturing site will remain unaffected, continuing to employ around 400 workers. The new Manchester facility is approximately 50% larger than the current Deeside operation and has capacity for up to 250 employees, allowing for future expansion.

Convatec's investment comes as part of a broader $1 billion worldwide R&D commitment, with the UK portion representing nearly half of this global initiative. The company, which generated $2.3 billion in revenue last year, typically allocates approximately 5% of its annual revenue to research and development. The relocation to Manchester positions Convatec to leverage the city's concentration of medical research institutions, including neighboring organizations such as the University of Manchester NHS Foundation Trust, biotech company QIAGEN, and MAC Clinical Research, strengthening its pipeline of new products addressing unmet needs in chronic care.